Navigation Links
Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
Date:8/16/2013

Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports. As many as 96% of men with testicular cancer now survive at least ten years from diagnosis (1), but more advanced forms need to be treated with combination chemotherapy which can have serious long-term complications. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have therefore been searching for new treatments that would reduce the risk of relapse after initial treatment and so spare as many men as possible from needing combination chemotherapy.

The new pilot study, published in the August issue of prestigious journal the Annals of Oncology, tested a new treatment in a pilot study of men with stage IIA and IIB testicular seminoma where the cancer has spread to the lymph nodes in the abdomen.

The researchers showed that giving chemotherapy drug carboplatin before radiotherapy could reduce relapse rates compared with radiotherapy alone cutting the numbers of men who would need follow-up treatment. It also allowed radiation doses to be reduced. The study was funded by The Institute of Cancer Research (ICR), the Bob Champion Cancer Trust and Cancer Research UK, as well as through the NIHR Biomedical Research Centre at The Royal Marsden and the ICR.

Researchers gave 51 men with stage IIA and IIB testicular seminoma a single cycle of carboplatin a low toxicity form of chemotherapy followed three to four weeks later by radiotherapy. Most of the men were aged below 50, over a range of 18-73 years.

Adding carboplatin to patients' treatment plans allowed doctors to give a lower dose of radiation over a smaller area of the body for most of the men in the study. Some 39 of the men in the study had their prescription of radiation reduced from the standard 35 Grays (Gy) of radiat
'/>"/>

Contact: Henry French
henry.french@icr.ac.uk
020-715-35312
Institute of Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Neuroblastoma: Autophagy protects from chemotherapy
2. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
3. Discovery may help prevent chemotherapy-induced anemia
4. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
5. New way to kill lymphoma without chemotherapy
6. Neutrons help explain why antibiotics prescribed for chemotherapy cause kidney failure
7. Scientists uncover strategy able to dramatically reduce chemotherapys side effects
8. New biomarker for common lung cancer predicts responses to chemotherapy
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Harmless human virus may be able to boost the effects of chemotherapy
11. Hot flashes before menopause? It can happen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... 2008Clinical researchers at Scottsdale Healthcare and TGen today announced ... for patients battling cancer. The Phase I ... Meeting of the American Association for Cancer Research by ... carcinoma (BCC) and pancreatic cancer. The Arizona trials were ...
... professor of molecular medicine Victor R. Ambros, PhD, ... world of investigation into developmental biology, will receive ... the most prestigious in science. Dr. Ambros shares ... of genetics at Harvard Medical School, with whom ...
... availability of new genome sequencing technology has prompted ... intriguing hypothesis about how agricultures early beginnings may ... Boris Vinatzer, assistant professor of plant pathology, physiology, ... and Life Sciences, has received a $1 million, ...
Cached Biology News:2 new therapies show promise for cancer patients 22 new therapies show promise for cancer patients 3UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 2UMass Medical School researcher Victor Ambros receives Gairdner Award, Franklin Medal 3Tomato pathogen genome may offer clues about bacterial evolution 2
(Date:3/4/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:3/4/2015)... Calif. , March 4, 2015 ... a specialty pharmaceutical company focused on the development ... of acute and breakthrough pain, today announced that ... financial results after market close on Monday, March ... conference call at 4:30 p.m. Eastern Time (1:30 ...
(Date:3/4/2015)... -- Lancée par l,Assistance Publique ... en décembre 2011, l,étude collaborative française randomisée et ...   l es microsphères en résine marquées ... carcinome hépatocellulaire avancé, a recruté plus de 400 ... ; les résultats sont attendus fin 2016.   ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Experts and ... schedules for one event: the Alltech REBELation exploring innovation, ... May 17-20. Now in its 31st year, Alltech’s annual ... 70 countries, and the opportunity to join the REBELation ... 7 at 11:59 p.m. EST, at which point the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... equipment, capable of generating intense pulses of light as short ... Red, will help scientists at the University of East Anglia ... and point the way to molecular structures for exploiting solar ... Engineering and Physical Sciences Research Council, the new laser will ...
... Feb. 28, 2012 Regado Biosciences, Inc., a privately held ... agents, announced that David J. Mazzo, PhD, President and CEO, ... Annual Health Care Conference at 1:30 p.m. EST on ... Boston, MA.  The presentation will include an ...
... NOVATO, Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical ... for rare and ultra-rare genetic disorders, today announced ... has granted orphan drug designation for UX003 for ... an extremely rare autosomal recessive lysosomal storage disorder ...
Cached Biology Technology:New laser can point the way to new energy harvesting 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 3Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3
Request Info...
... Life Science FLA-7000 excels at fluorescent and ... documentation. It features four easy-to-access filters (filters ... filter for Imaging Plates) for upgrading flexibility. ... choice of four kinds of excitation laser ...
... The ULS cDNA Synthesis and Labeling ... microarray hybridization experiments. First unmodified cDNA is ... into cDNA using an Oligo(dT) primer. Unlike ... nucleotides used in the reverse transcription reaction. ...
... that enables fully automated hybridization of microarrays ... has been designed to offer researchers improved ... to perform a wide range of applications. ... range 485C; denaturations of up to 99C. ...
Biology Products: